Have a feature idea you'd love to see implemented?
Let us know!
BIIB Biogen Inc
Price (delayed)
$158.01
Market cap
$23.03B
P/E Ratio
14.22
Dividend/share
N/A
EPS
$11.11
Enterprise value
$27.98B
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Highlights
The P/E is 46% below the last 4 quarters average of 26.4 and 21% below the 5-year quarterly average of 18.0
Biogen's net income has increased by 39% QoQ and by 10% YoY
The company's quick ratio fell by 47% QoQ and by 24% YoY
Biogen's revenue has decreased by 3.9% YoY
Key stats
What are the main financial stats of BIIB
Market
Valuations
Earnings
Shares outstanding
145.72M
Market cap
$23.03B
Enterprise value
$27.98B
Price to earnings (P/E)
14.22
Price to book (P/B)
1.41
Price to sales (P/S)
2.4
EV/EBIT
14.67
EV/EBITDA
10.94
EV/Sales
2.91
Revenue
$9.61B
EBIT
$1.91B
EBITDA
$2.56B
Free cash flow
$1.86B
Per share
Balance sheet
Liquidity
EPS
$11.11
Free cash flow per share
$12.75
Book value per share
$112.31
Revenue per share
$65.94
TBVPS
$82.51
Total assets
$28.31B
Total liabilities
$11.95B
Debt
$6.65B
Equity
$16.36B
Working capital
$1.41B
Debt to equity
0.41
Current ratio
1.26
Quick ratio
0.68
Net debt/EBITDA
1.94
Margins
Efficiency
Dividend
EBITDA margin
26.6%
Gross margin
75.6%
Net margin
16.8%
Operating margin
19.8%
Return on assets
6%
Return on equity
10.4%
Return on invested capital
13.8%
Return on capital employed
8.3%
Return on sales
19.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BIIB stock price
How has the Biogen stock price performed over time
Intraday
1.29%
1 week
-4.17%
1 month
-14.43%
1 year
-31.17%
YTD
-38.94%
QTD
-18.48%
Financial performance
How have Biogen's revenue and profit performed over time
Revenue
$9.61B
Gross profit
$7.26B
Operating income
$1.91B
Net income
$1.62B
Gross margin
75.6%
Net margin
16.8%
Biogen's operating margin has increased by 46% from the previous quarter and by 23% YoY
BIIB's operating income is up by 45% since the previous quarter and by 18% year-on-year
Biogen's net margin has increased by 40% from the previous quarter and by 15% YoY
Biogen's net income has increased by 39% QoQ and by 10% YoY
Growth
What is Biogen's growth rate over time
Valuation
What is Biogen stock price valuation
P/E
14.22
P/B
1.41
P/S
2.4
EV/EBIT
14.67
EV/EBITDA
10.94
EV/Sales
2.91
The P/E is 46% below the last 4 quarters average of 26.4 and 21% below the 5-year quarterly average of 18.0
The EPS has grown by 39% from the previous quarter and by 9% YoY
BIIB's price to book (P/B) is 56% lower than its 5-year quarterly average of 3.2 and 33% lower than its last 4 quarters average of 2.1
The equity has grown by 13% YoY and by 3% from the previous quarter
The stock's price to sales (P/S) is 31% less than its 5-year quarterly average of 3.5 and 29% less than its last 4 quarters average of 3.4
Biogen's revenue has decreased by 3.9% YoY
Efficiency
How efficient is Biogen business performance
The ROIC has soared by 53% from the previous quarter and by 45% YoY
The ROS has grown by 46% from the previous quarter and by 23% YoY
Biogen's return on assets has increased by 40% QoQ and by 5% YoY
The ROE has grown by 35% from the previous quarter
Dividends
What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BIIB.
Financial health
How did Biogen financials performed over time
The total assets is 137% more than the total liabilities
The company's quick ratio fell by 47% QoQ and by 24% YoY
The current ratio has contracted by 45% from the previous quarter and by 25% YoY
Biogen's debt is 59% less than its equity
The debt to equity has decreased by 23% YoY and by 2.4% from the previous quarter
Biogen's debt has decreased by 14% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.